Literature DB >> 24292707

Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3β.

Jonathan A Kirk, Ronald J Holewinski, Viola Kooij, Giulio Agnetti, Richard S Tunin, Namthip Witayavanitkul, Pieter P de Tombe, Wei Dong Gao, Jennifer Van Eyk, David A Kass.   

Abstract

Cardiac resynchronization therapy (CRT), the application of biventricular stimulation to correct discoordinate contraction, is the only heart failure treatment that enhances acute and chronic systolic function, increases cardiac work, and reduces mortality. Resting myocyte function also increases after CRT despite only modest improvement in calcium transients, suggesting that CRT may enhance myofilament calcium responsiveness. To test this hypothesis, we examined adult dogs subjected to tachypacing-induced heart failure for 6 weeks, concurrent with ventricular dyssynchrony (HF(dys)) or CRT. Myofilament force-calcium relationships were measured in skinned trabeculae and/or myocytes. Compared with control, maximal calcium-activated force and calcium sensitivity declined globally in HF(dys); however, CRT restored both. Phosphatase PP1 induced calcium desensitization in control and CRT-treated cells, while HF(dys) cells were unaffected, implying that CRT enhances myofilament phosphorylation. Proteomics revealed phosphorylation sites on Z-disk and M-band proteins, which were predicted to be targets of glycogen synthase kinase-3β (GSK-3β). We found that GSK-3β was deactivated in HF(dys) and reactivated by CRT. Mass spectrometry of myofilament proteins from HF(dys) animals incubated with GSK-3β confirmed GSK-3β–dependent phosphorylation at many of the same sites observed with CRT. GSK-3β restored calcium sensitivity in HF(dys), but did not affect control or CRT cells. These data indicate that CRT improves calcium responsiveness of myofilaments following HF(dys) through GSK-3β reactivation, identifying a therapeutic approach to enhancing contractile function

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24292707      PMCID: PMC3871225          DOI: 10.1172/JCI69253

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  p21-activated kinase increases the calcium sensitivity of rat triton-skinned cardiac muscle fiber bundles via a mechanism potentially involving novel phosphorylation of troponin I.

Authors:  Nina Buscemi; D Brian Foster; Irina Neverova; Jennifer E Van Eyk
Journal:  Circ Res       Date:  2002-09-20       Impact factor: 17.367

2.  Transgenic mouse model of stunned myocardium.

Authors:  A M Murphy; H Kögler; D Georgakopoulos; J L McDonough; D A Kass; J E Van Eyk; E Marbán
Journal:  Science       Date:  2000-01-21       Impact factor: 47.728

3.  Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart.

Authors:  Pingbo Zhang; Jonathan A Kirk; Weihua Ji; Cristobal G dos Remedios; David A Kass; Jennifer E Van Eyk; Anne M Murphy
Journal:  Circulation       Date:  2012-09-12       Impact factor: 29.690

4.  Why does troponin I have so many phosphorylation sites? Fact and fancy.

Authors:  R John Solaro; Jolanda van der Velden
Journal:  J Mol Cell Cardiol       Date:  2010-02-25       Impact factor: 5.000

5.  Focal adhesion kinase and p130Cas mediate both sarcomeric organization and activation of genes associated with cardiac myocyte hypertrophy.

Authors:  B Kovacic-Milivojević; F Roediger; E A Almeida; C H Damsky; D G Gardner; D Ilić
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

6.  Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy.

Authors:  Frank B Sachse; Natalia S Torres; Eleonora Savio-Galimberti; Takeshi Aiba; David A Kass; Gordon F Tomaselli; John H Bridge
Journal:  Circ Res       Date:  2012-01-17       Impact factor: 17.367

7.  Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants.

Authors:  C P Liu; C T Ting; W Lawrence; W L Maughan; M S Chang; D A Kass
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

8.  Phosphorylation or glutamic acid substitution at protein kinase C sites on cardiac troponin I differentially depress myofilament tension and shortening velocity.

Authors:  Eileen M Burkart; Marius P Sumandea; Tomoyoshi Kobayashi; Mahta Nili; Anne F Martin; Earl Homsher; R John Solaro
Journal:  J Biol Chem       Date:  2003-01-27       Impact factor: 5.157

9.  Actin capping protein: an essential element in protein kinase signaling to the myofilaments.

Authors:  W Glen Pyle; Marilyn C Hart; John A Cooper; Marius P Sumandea; Pieter P de Tombe; R John Solaro
Journal:  Circ Res       Date:  2002-06-28       Impact factor: 17.367

10.  The effect of myosin light chain 2 dephosphorylation on Ca2+ -sensitivity of force is enhanced in failing human hearts.

Authors:  J van der Velden; Z Papp; N M Boontje; R Zaremba; J W de Jong; P M L Janssen; G Hasenfuss; G J M Stienen
Journal:  Cardiovasc Res       Date:  2003-02       Impact factor: 10.787

View more
  32 in total

1.  β-Arrestin mediates the Frank-Starling mechanism of cardiac contractility.

Authors:  Dennis M Abraham; Robert T Davis; Chad M Warren; Lan Mao; Beata M Wolska; R John Solaro; Howard A Rockman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-28       Impact factor: 11.205

2.  Recovery of myofilament function through reactivation of glycogen synthase kinase 3β (GSK-3β): mechanism for cardiac resynchronization therapy.

Authors:  Syed Raza Shah; Kaneez Fatima; Mehreen Ansari
Journal:  J Interv Card Electrophysiol       Date:  2014-09-26       Impact factor: 1.900

Review 3.  Recent advances in the optimization of cardiac resynchronization therapy.

Authors:  Satish Chandraprakasam; Gina G Mentzer
Journal:  Curr Heart Fail Rep       Date:  2015-02

4.  Glycoproteins identified from heart failure and treatment models.

Authors:  Shuang Yang; Lijun Chen; Shisheng Sun; Punit Shah; Weiming Yang; Bai Zhang; Zhen Zhang; Daniel W Chan; David A Kass; Jennifer E van Eyk; Hui Zhang
Journal:  Proteomics       Date:  2014-10-09       Impact factor: 3.984

Review 5.  Unraveling obscurins in heart disease.

Authors:  Alyssa Grogan; Aikaterini Kontrogianni-Konstantopoulos
Journal:  Pflugers Arch       Date:  2018-08-11       Impact factor: 3.657

Review 6.  Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.

Authors:  Heinrich Taegtmeyer; Martin E Young; Gary D Lopaschuk; E Dale Abel; Henri Brunengraber; Victor Darley-Usmar; Christine Des Rosiers; Robert Gerszten; Jan F Glatz; Julian L Griffin; Robert J Gropler; Hermann-Georg Holzhuetter; Jorge R Kizer; E Douglas Lewandowski; Craig R Malloy; Stefan Neubauer; Linda R Peterson; Michael A Portman; Fabio A Recchia; Jennifer E Van Eyk; Thomas J Wang
Journal:  Circ Res       Date:  2016-03-24       Impact factor: 17.367

Review 7.  The GSK-3 family as therapeutic target for myocardial diseases.

Authors:  Hind Lal; Firdos Ahmad; James Woodgett; Thomas Force
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

8.  Cardiac resynchronization therapy induces adaptive metabolic transitions in the metabolomic profile of heart failure.

Authors:  Emirhan Nemutlu; Song Zhang; Yi-Zhou Xu; Andre Terzic; Li Zhong; Petras D Dzeja; Yong-Mei Cha
Journal:  J Card Fail       Date:  2015-04-22       Impact factor: 5.712

Review 9.  Cellular and Molecular Aspects of Dyssynchrony and Resynchronization.

Authors:  Jonathan A Kirk; David A Kass
Journal:  Card Electrophysiol Clin       Date:  2015-12

Review 10.  Adrenergic signaling in heart failure and cardiovascular aging.

Authors:  Gaetano Santulli; Guido Iaccarino
Journal:  Maturitas       Date:  2016-03-26       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.